Loading...
Market
Story
NHS Plans 12-Year Rollout for 'King Kong' Weight-Loss Drug, Limited to 220,000 Patients
Dec 5, 2024, 01:11 AM
The National Health Service (NHS) in England has announced a 12-year rollout plan for a new weight-loss drug, which has been described as the 'King Kong' of weight-loss treatments. This drug, anticipated to be a significant player in the Chinese market worth over $11 billion annually by 2033 according to Nomura, will initially be limited to just 220,000 patients, fewer than one in ten who meet the eligibility criteria. The slow rollout is due to concerns that the demand for the drug could overwhelm the health service, leading to a long wait for millions of severely obese patients.
View original story
Similar markets
Regulatory issues • 25%
Supply chain issues • 25%
Funding issues • 25%
Other • 25%
Lecanemab • 25%
Aducanumab • 25%
Another new drug • 25%
No approval • 25%
Cost • 25%
Regulatory approvals • 25%
Manufacturing capacity • 25%
Public awareness • 25%
Cost • 25%
Distribution • 25%
Regulatory approval • 25%
Adherence • 25%
Safety concerns • 25%
Ethical concerns • 25%
Funding issues • 25%
Political pressure • 25%